See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Gilead Sciences, Inc. (GILD) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences, Inc. (GILD) - free report >>
Image: Bigstock
Biotech ETF (BBH) Hits New 52-Week High
For investors seeking momentum, VanEck Vectors Biotech ETF (BBH - Free Report) is probably on radar now. The fund just hit a 52-week high and is up about 27.2% from its 52-week low price of $95.77/share.
But are more gains in store for this ETF? Let’s take a quick look at the fund and the near-term outlook on it to get a better idea on where it might be headed:
BBH in Focus
BBH focuses on the biotechnology segment of the U.S. market. The fund has a large-cap focus with key holdings in Amgen (AMG - Free Report) , Celgene and Gilead Sciences (GILD - Free Report) that account for a double-digit allocation each. It charges investors 35 basis points a year in fees (see: all the Healthcare ETFs here).
Why the Move?
The biotech sector has been an area to watch lately given its impressive comeback after a slew of Trump statements and the fate of Obamacare that spooked the sector early this year. Then a couple of recent actions charged up the space, pushing the stocks higher. In particular, the President has promised to reduce federal regulations by 75–80% and streamline the Food & Drug Administration (FDA) approval process. This would make it easier for biotech companies to bring new products to the market. Trump’s proposed tax reforms and cash repatriation policy are also supporting the rally.
More Gains Ahead?
Currently, BBH has a Zacks ETF Rank of 3 or ‘Hold’ rating with a Medium risk outlook. Therefore, it is hard to get a handle on its future returns one way or the other. However, many of the segments that make up this ETF have a strong Zacks Industry Rank, so there is definitely some promise for those who want to ride this surging ETF a little further.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>